About Cyclica
Cyclica is a company based in Toronto (Canada) founded in 2010 was acquired by Recursion in May 2023. Cyclica has raised $21.06 million across 7 funding rounds from investors including Recursion Pharmaceuticals, Gates Foundation and Chiesi Pharmaceuticals. Cyclica operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Cyrus Biotechnology and Vividion Therapeutics, among others.
- Headquarter Toronto, Canada
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cyclica Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.06 M (USD)
in 7 rounds
-
Latest Funding Round
$1.81 M (USD), Grant
Nov 15, 2022
-
Investors
Recursion Pharmaceuticals
& 9 more
-
Employee Count
Not available
-
Acquired by
Recursion
(May 08, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cyclica
Unlock access to complete
Unlock access to complete
Funding Insights of Cyclica
Cyclica has successfully raised a total of $21.06M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $1.81 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cyclica
Cyclica has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Gates Foundation and Chiesi Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on pre-seed and seed stage investments
|
Locked | Locked | Locked | |
|
Early stage Canadian B2B startups are funded by GreenSky Ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Cyclica
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyclica
Investment portfolio details for Cyclica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cyclica
Detailed financials for Cyclica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cyclica Comparisons
Peer comparison for Cyclica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cyclica
Cyclica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Cyrus Biotechnology and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Cyclica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cyclica
Complete news archive for Cyclica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyclica
Cyclica was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Cyclica is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Cyclica is a funded company, having raised a total of $21.06M across 7 funding rounds to date.
Online AI-interface predictive analytics platform for drug discovery and testing. It is a biotechnology company that offers a biomolecular analytics platform for proteome docking. It uses proprietary algorithms and databases to improve drug discovery pipelines by identifying risks such as adverse effects, contraindications, and lack of efficacy. It uses multi-channel systems for evaluating and comparing small molecules to predict the reaction with the human body and searches for all proteins that have potential drug-protein interactions. It also offers a proprietary database of bacterial and viral proteomes that can be used to identify new treatments for infectious diseases.
Cyclica's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Cyclica has 10 investors. Key investors include Recursion Pharmaceuticals, Gates Foundation, Chiesi Pharmaceuticals, StartUp Health, and Drive Capital.